WO2019090244A3 - Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes - Google Patents

Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes Download PDF

Info

Publication number
WO2019090244A3
WO2019090244A3 PCT/US2018/059242 US2018059242W WO2019090244A3 WO 2019090244 A3 WO2019090244 A3 WO 2019090244A3 US 2018059242 W US2018059242 W US 2018059242W WO 2019090244 A3 WO2019090244 A3 WO 2019090244A3
Authority
WO
WIPO (PCT)
Prior art keywords
myeloid
derived suppressor
vitro
suppressor cell
cluster analysis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/059242
Other languages
English (en)
Other versions
WO2019090244A2 (fr
Inventor
Sharon Evans
Scott Abrams
Max Wicha
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Health Research Inc
Original Assignee
Health Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Research Inc filed Critical Health Research Inc
Publication of WO2019090244A2 publication Critical patent/WO2019090244A2/fr
Publication of WO2019090244A3 publication Critical patent/WO2019090244A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé d'identification de l'état immunosuppresseur d'un individu comprenant la détection de la formation d'une formation de groupe de cellules suppressives dérivées de myéloïdes circulantes (MDSC) dans un échantillon de sang obtenu à partir d'un individu. La formation de groupe MDSC peut être identifiée dans des frottis sanguins frais ou dans des échantillons de sang par cytométrie de flux.
PCT/US2018/059242 2017-11-03 2018-11-05 Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes Ceased WO2019090244A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762581438P 2017-11-03 2017-11-03
US62/581,438 2017-11-03

Publications (2)

Publication Number Publication Date
WO2019090244A2 WO2019090244A2 (fr) 2019-05-09
WO2019090244A3 true WO2019090244A3 (fr) 2019-06-13

Family

ID=66331490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/059242 Ceased WO2019090244A2 (fr) 2017-11-03 2018-11-05 Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes

Country Status (1)

Country Link
WO (1) WO2019090244A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594271B2 (en) 2019-11-05 2026-04-07 Health Research, Inc. Combination therapy for cancer
WO2022132041A1 (fr) * 2020-12-15 2022-06-23 Agency For Science, Technology And Research Procédé destiné à caractériser un neutrophile immunosuppressif
CN114739890B (zh) * 2022-04-15 2022-12-13 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） 人MDSCs在鉴别CAA和AAA中的应用及鉴别试剂盒

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160096892A1 (en) * 2014-07-21 2016-04-07 The Trustees Of The University Of Pennsylvania Treatment of cancer using a cd33 chimeric antigen receptor
US20170112929A1 (en) * 2012-09-07 2017-04-27 Kings College London Vista modulators for diagnosis and treatment of cancer
US20170131285A1 (en) * 2014-06-13 2017-05-11 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for diagnosing, monitoring and treating cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170112929A1 (en) * 2012-09-07 2017-04-27 Kings College London Vista modulators for diagnosis and treatment of cancer
US20170131285A1 (en) * 2014-06-13 2017-05-11 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for diagnosing, monitoring and treating cancer
US20160096892A1 (en) * 2014-07-21 2016-04-07 The Trustees Of The University Of Pennsylvania Treatment of cancer using a cd33 chimeric antigen receptor

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHEN ET AL.: "Recruitment of CD 11b+Ly6C+ monocytes in non-small cell lung cancer xenografts challenged by anti-VEGF antibody", ONCOL LETT., vol. 14, no. 1, 24 May 2017 (2017-05-24), pages 615 - 622, XP055614931, DOI: 10.3892/ol.2017.6236 *
DING ET AL.: "Critical Role of the mTOR Pathway in Development and Function of Myeloid- Derived Suppressor Cells in lalL/L Mice", AM J PATHOL., vol. 184, no. 2, February 2014 (2014-02-01), pages 397 - 408, XP055614926, DOI: 10.1016/j.ajpath.2013.10.015 *
KOTSAKIS ET AL.: "Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples", J IMMUNOL METHODS, vol. 381, no. 1-2, 2012, pages 1 - 22, XP028509497, DOI: 10.1016/j.jim.2012.04.004 *
SINHA ET AL.: "Tumor-Induced Myeloid-derived Suppressor Cell Function is Independent of IFNgamma and IL -4Ra", EUR J IMMUNOL., vol. 42, no. 8, August 2012 (2012-08-01), pages 2052 - 2059, XP055614918, DOI: 10.1002/eji.201142230 *
STANOJEVIC ET AL.: "A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma", INT IMMUNOL., vol. 28, no. 2, 2015, pages 87 - 97, XP055614924, DOI: 10.1093/intimm/dxv053 *
TUCK ET AL.: "Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group", J PROTEOME RES., vol. 8, no. 1, 2009, pages 113 - 117, XP055614928, DOI: 10.1021/pr800545q *
UMANSK Y ET AL.: "The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression", VACCINES ( BASEL, vol. 4, no. 4, 3 November 2016 (2016-11-03), pages E36, XP055614921, DOI: 10.3390/vaccines4040036 *

Also Published As

Publication number Publication date
WO2019090244A2 (fr) 2019-05-09

Similar Documents

Publication Publication Date Title
GB2516196A (en) Methods, compositions, kits, and systems for selective enrichment of target cells
ES2660429T3 (es) Métodos, reactivos y kits para detectar enfermedad residual mínima
EP4397774A3 (fr) Procédés de codage à barres de molécules d'acide nucléique à partir de cellules individuelles ou de populations de cellules
EP4546353A3 (fr) Systèmes et procédés d'analyse de populations de cellules mixtes
EP4332546A3 (fr) Systèmes et procédés de traitement de particules sans opérateur
MX2021009726A (es) Metodos y sistemas para determinar un estado relacionado con el embarazo de un sujeto.
WO2014065889A3 (fr) Procédé multiplexé pour le diagnostic du lymphome de hodgkin classique
US11022600B2 (en) Method for assessing state of differentiation of cells
WO2020092975A3 (fr) Procédés de dosage de cellules biologiques dans un dispositif microfluidique
MX2016016902A (es) Metodos para analizar acidos nucleicos de celulas individuales o poblaciones de celulas.
GB2532672A (en) Methods and systems for analysis of organ transplantation
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
NZ749272A (en) Phospholipid ether analogs for the identification and isolation of circulating tumor cells
TR201905062T4 (tr) Erken granüle hücrelerin (EGC'ler) tanımlanması ve sayılması.
WO2012151105A3 (fr) Systèmes et procédés d'analyse des basophiles
WO2019055661A8 (fr) Biomarqueurs de pré-éclampsie ainsi que systèmes et procédés associés
WO2019193332A3 (fr) Séparation et détection de micro-organismes
MX2022012824A (es) Metodos para enriquecer vesiculas extracelulares de muestras de liquido biologico.
ZA202001214B (en) Systems and methods for performing a real-time glycan assay of a sample
HK1257122A1 (zh) Lrp5作为用於鉴定免疫细胞特别是b细胞的表观遗传标志物
EP4339295A3 (fr) Dispositif de stockage, système et procédé pour déterminer l'état métabolique de globules rouges et de plaquettes
SG11201811433TA (en) Mmp1 gene transcript for use as marker for diagnosis of ovarian cancer prognosis, and test method
WO2014169072A3 (fr) Trousses et procédés pour séparer un analyte cible à partir d'une suspension
ZA202004086B (en) Method for the harmonization of assay results
EP4254335A3 (fr) Analyse structurelle quantitative de greffon nerveux

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18872951

Country of ref document: EP

Kind code of ref document: A2